Evidence map›Paper›PMID 42259916›Full record

ArticleNature2026

Targeting cancer-specific mutations with RNA-triggered chromatin shredding.

Jingkun Zeng, Zhiyuan Cheng, Huadong Chen, Zhaojun Wang, Jared Thompson, Kadin T Crosby, Hesong Han, Arushi Singhal, Wayne Ngo, Chenglong Xia and 15 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors.

Jingkun ZengGladstone Institute of Data Science and Biotechnology, San Francisco, CA, USA.
Zhiyuan Cheng *Gladstone Institute of Data Science and Biotechnology, San Francisco, CA, USA.ORCID http://orcid.org/0009-0000-3474-2422
Huadong Chen *Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.
Zhaojun Wang *Gladstone Institute of Data Science and Biotechnology, San Francisco, CA, USA.
Jared ThompsonDepartment of Biochemistry, University of Utah School of Medicine, Salt Lake City, UT, USA.ORCID http://orcid.org/0009-0006-8557-9702
Kadin T CrosbyDepartment of Chemistry and Biochemistry, Utah State University, Logan, UT, USA.ORCID http://orcid.org/0009-0001-0201-5340
Hesong HanInnovative Genomics Institute, University of California, Berkeley, Berkeley, CA, USA.ORCID http://orcid.org/0000-0001-5545-5238
Arushi SinghalGladstone Institute of Data Science and Biotechnology, San Francisco, CA, USA.
Wayne NgoGladstone Institute of Data Science and Biotechnology, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-5755-2303
Chenglong XiaInnovative Genomics Institute, University of California, Berkeley, Berkeley, CA, USA.ORCID http://orcid.org/0000-0002-5895-6342
Daniel Rosas-RiveraGladstone Institute of Data Science and Biotechnology, San Francisco, CA, USA.
Zeyuan ZhangInnovative Genomics Institute, University of California, Berkeley, Berkeley, CA, USA.
Min Hyung KangInnovative Genomics Institute, University of California, Berkeley, Berkeley, CA, USA.
Ying MaoHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.
Morgan E DiolaitiHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-5900-3060
Giselle C LeeThe Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0002-1794-3094
John F X DiffleyThe Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0001-5184-7680
Yixuan SongThe Francis Crick Institute, London, UK.
Longhui QiuDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Nathan M KrahDepartment of Biochemistry, University of Utah School of Medicine, Salt Lake City, UT, USA.ORCID http://orcid.org/0009-0003-8297-7359
Niren MurthyInnovative Genomics Institute, University of California, Berkeley, Berkeley, CA, USA.ORCID http://orcid.org/0000-0002-7815-7337
Ryan N JacksonDepartment of Chemistry and Biochemistry, Utah State University, Logan, UT, USA.ORCID http://orcid.org/0000-0001-7403-3794
Yang LiuDepartment of Biochemistry, University of Utah School of Medicine, Salt Lake City, UT, USA.ORCID http://orcid.org/0000-0002-3889-9707
Alan AshworthHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-1446-7878
Jennifer A DoudnaGladstone Institute of Data Science and Biotechnology, San Francisco, CA, USA. doudna@berkeley.edu.ORCID http://orcid.org/0000-0001-9161-999X

Funding

Project 3U54AI170792 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Nevan J Krogan · 2022 to 2026
$35.7M
Resource Core II: In Vivo CoreU19NS132303 · NINDS · UNIVERSITY OF CALIFORNIA BERKELEY · PI FYODOR D URNOV · 2023 to 2026
$19.7M
Determining the Structure and Function of Newly Discovered Immune SystemsR35GM138080 · NIGMS · UTAH STATE UNIVERSITY · PI Ryan Neal Jackson · 2020 to 2026
$2.8M
Expanding CRISPR-Cas editing technology through exploration of novel Cas proteins and DNA repair systemsU01AI142817 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI BANFIELD, JILLIAN, DOUDNA, JENNIFER A · 2018 to 2022
$2.0M
Mapping the Cellular Responses to DNA Double-Strand Breaks Using On-Demand CRISPR technologies and High-resolution Fluorescence MicroscopyR35GM150941 · NIGMS · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Yang Liu · 2023 to 2026
$1.7M
Cas9 RNP delivery to immune cells in vivo via molecular targetingUH3AI150552 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI DOUDNA, JENNIFER A, WILSON, ROSS C · 2022 to 2022
$1.3M
Targeted Delivery of Cas9 to Lung Epithelial Cells using Enveloped Delivery VehiclesR21HL173710 · NHLBI · J. DAVID GLADSTONE INSTITUTES · PI DOUDNA, JENNIFER A · 2024 to 2025
$520k
Howard Hughes Medical InstituteNHLBI NIH HHS R21 HL173710NIAID NIH HHS U01 AI142817NIAID NIH HHS U54 AI170792NIAID NIH HHS UH3 AI150552NIGMS NIH HHS R35 GM138080NIGMS NIH HHS R35 GM150941NINDS NIH HHS U19 NS132303
6 · The paper itself

Abstract

Genetic mutations that drive cancer often occur in tumour-suppressor proteins such as the p53 transcription factor, which is altered in 40-50% of cases

Indexed as

ChromatinDNA DamageMutationNeoplasmsRNA, Guide, CRISPR-Cas SystemsAnimalsCell Line, TumorCRISPR-Cas SystemsHumansChromatinRNA, Guide, CRISPR-Cas Systems

Identifiers

PMID42259916
PMCPMC13533554

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.